Showing results (451-460 of 472) with videos related to

Sort By:
Pageof 48
Breast (Edinburgh, Scotland)|March 2, 2019
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA studyA Mavratzas, S Baek, B Gerber, et al.
The British Journal of Dermatology|February 3, 2009
Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factorsC Sunderkötter, I Herrgott, C Brückner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2010
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trialG von Minckwitz, H Eidtmann, S Loibl, et al.
Frontiers in Neuroinformatics|May 21, 2019
NeuroMeasure: A Software Package for Quantification of Cortical Motor Maps Using Frameless Stereotaxic Transcranial Magnetic StimulationMichael B Gerber, Alasdair C McLean, Samuel J Stephen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2007
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO studyG von Minckwitz, S Kümmel, A du Bois, et al.
Clinical Genetics|June 6, 2022
Further characterization of Borjeson-Forssman-Lehmann syndrome in females due to de novo variants in PHF6Céline B Gerber, Anna Fliedner, Oliver Bartsch, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2010
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trialM Kaufmann, N Maass, S D Costa, et al.
Zentralblatt Fur Gynakologie|December 26, 2001
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group]G von Minckwitz, G Raab, M Schütte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)B Gerber, S Loibl, H Eidtmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 2013
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)G von Minckwitz, M Rezai, P A Fasching, et al.
Pageof 48